Home › Research › Brain scans and imaging
Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease
Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H.. The Medical clinics of North America, 2013-02-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
There is no evidence for individual risk prediction and even less for specific treatments. Thus, the development of preclinical diagnostic imaging poses not only technical but also ethical problems that must be critically discussed on the basis of profound knowledge. From a neurobiological point of view, the main determinants of cognitive impairment in AD are the density of synapses and neurons in distributed cortical and subcortical networks. MRI-based measures of regional gray matter volume and associated multivariate analysis techniques of regional interactions of gray matter densities provide insight into the onset and temporal dynamics of cortical atrophy as a close proxy for regional neuronal loss and a basis of functional impairment in specific neuronal networks. From the clinical point of view, clinicians must bear in mind that patients do not suffer from hippocampus atrophy or disconnection but from memory impairment, and that dementia screening in asymptomatic subjects should not be used outside of clinical studies.
What this study adds
Evidence grade: Moderate
This is a narrative review. This review states there is no evidence for individual risk prediction and even less for specific treatments, and that dementia screening in asymptomatic subjects should not be used outside of clinical studies. It describes MRI measures of regional gray matter volume as a proxy for neuronal loss and a basis of functional impairment in specific networks.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Teipel, S. J., Grothe, M., Lista, S., Toschi, N., Garaci, F. G., & Hampel, H. (2013). Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. The Medical clinics of North America. https://doi.org/10.1016/j.mcna.2012.12.013
Vancouver
Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. The Medical clinics of North America. 2013. doi:10.1016/j.mcna.2012.12.013. PMID: 23642578.
BibTeX
@article{teipel2013-23642578,
author = {Teipel, S. J. and Grothe, M. and Lista, S. and Toschi, N. and Garaci, F. G. and Hampel, H.},
title = {{Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease}},
journal = {The Medical clinics of North America},
year = {2013},
doi = {10.1016/j.mcna.2012.12.013},
pmid = {23642578},
url = {https://doi.org/10.1016/j.mcna.2012.12.013}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There is no evidence for individual risk prediction and even less for specific treatments.
- Thus, the development of preclinical diagnostic imaging poses not only technical but also ethical problems that must be critically discussed on the basis of profound knowledge.
- From a neurobiological point of view, the main determinants of cognitive impairment in AD are the density of synapses and neurons in distributed cortical and subcortical networks.
- MRI-based measures of regional gray matter volume and associated multivariate analysis techniques of regional interactions of gray matter densities provide insight into the onset and temporal dynamics of cortical atrophy as a close proxy for regional neuronal loss and a basis of functional impairment in specific neuronal networks.
- From the clinical point of view, clinicians must bear in mind that patients do not suffer from hippocampus atrophy or disconnection but from memory impairment, and that dementia screening in asymptomatic subjects should not be used outside of clinical studies.
Why it matters
This review states there is no evidence for individual risk prediction and even less for specific treatments, and that dementia screening in asymptomatic subjects should not be used outside of clinical studies. It describes MRI measures of regional gray matter volume as a proxy for neuronal loss and a basis of functional impairment in specific networks.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Evidence strengthModerate
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Medical clinics of North America) |
| Journal's citation record | 2 / 4 | Medical Clinics of North America: journal h-index 161 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 192 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.8 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 4 / 6 | Cited 14.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 33 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Harald Juergen Hampel: h-index 136 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Goethe University Frankfurt: institution h-index 958 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23642578) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 40.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Brain scans and imaging from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.